Table 3 Follow-up summary
Patient | Extent of surgery | Recurrence | Localization of recurrence | Time to recurrence | Treatment for recurrence/progressive disease | Current status | Follow-up period |
|---|---|---|---|---|---|---|---|
1 | Biopsy | No (initial peritoneal metastasis) |  |  | Sorafenib | DOD | 6 months |
2 | Atypical resection segments 2/3 and 4b | No |  |  |  | NED | 57 months |
3 | Anatomical resection segments 2/3 | Yes | Multiple intrahepatic | 9 months | Resection, cisplatin/gemcitabine, sorafenib, study regimen (oral FGF401 vs. oral FGF401 with PDR001) | AWD | 47 months |
4 | Meso-hepatectomy 4a and 4b plus segment 1 resection | Yes | Intrahepatic | 30 months | Re-resection | AWD | 60 months |
5 | Anatomical resection segments 2/3 | Yes | Intrahepatic | 14 months | Radiotherapy, TACE, SIRT | AWD | 53 months |
6 | Left trisectionectomy with 4/5 en-block gastrectomy | No |  |  |  | NED | 1 month |
7 | Right trisectionetomy | Yes | Intrahepatic, lymph node, pulmonary, peritoneal | 3 months | Study regimen (lenvatinib vs. sorafenib) | DCU | 20 months |
8 | Left hemihepatectomy | Yes | Peritoneal | 4 months | Pembrolizumab | DOD | 7 months |